In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption

Lignende værker

• Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
  af: Larbouret, Christelle, et al.
  Udgivet: (2010)
• Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers: A NEW METHOD TO EVALUATE THE EFFICIENCY OF TARGETED THERAPY USING MONOCLONAL ANTIBODIES
  af: Gaborit, Nadège, et al.
  Udgivet: (2011)
• Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer.
  af: Alexandre Ho-Pun-Cheung, et al.
  Udgivet: (2012-01-01)
• Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer
  af: Ho-Pun-Cheung, Alexandre, et al.
  Udgivet: (2012)
• Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
  af: Assenat, Eric, et al.
  Udgivet: (2015)